| Date | Title | Description |
| 14.05.2025 | European governments scramble to interpret Trump's new drug pricing order | European governments scramble to interpret Trump's new drug pricing order
By Maggie FickMay 14, 20255:11 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Item 1 of 2 Pharmaceutical tablets and ca... |
| 13.05.2025 | The High Seas and Trade Winds: A Tale of Tragedy and Triumph | In the vast expanse of the Mediterranean, a tragedy unfolded. The sunken superyacht of tech mogul Mike Lynch, the Bayesian, became a grave marker for lost lives. The vessel sank off the coast of Sicily, claiming the lives of seven individua... |
| 13.05.2025 | ABBYY Drives Growth in EMEA With the Appointment of Arnaud Lagarde as New Vice President of Sales | Today, the global leader in purpose-built AI for intelligent automation, ABBYY, appointed Arnaud Lagarde as its new Vice President of Sales for EMEA.
The appointment comes as ABBYY expands its EMEA leadership team with the goals of strength... |
| 12.05.2025 | Планы Трампа по снижению цен на лекарства лишили AstraZeneca звания самой дорогой компании Великобритании | В понедельник акции упали на 5,8%, в результате чего рыночная капитализация AstraZeneca снизилась примерно до £154 млрд и оказалась ниже £156 млрд у HSBC Holdings Plc.
Акции европейских производителей лекарств пострадали в более широком пла... |
| 12.05.2025 | European stocks close higher after U.S.-China deal to cut tariffs | This is CNBC’s live blog covering European markets.
European stock markets closed higher Monday following the White House’s announcement that the U.S. and China had agreed to slash tariffs.
The Stoxx 600 closed up by 1.1% provisionally, wit... |
| 12.05.2025 | GSK and Astrazeneca shares slump as Trump vows drug price cut | Shares in London-listed drugmakers GSK and Astrazeneca tumbled on Monday morning after President Donald Trump said the US’ new pharma policy would make drug prices “rise throughout the world”.
GSK slumped three per cent and Astrazeneca near... |
| 09.05.2025 | FTSE 100 Stumbles as Pharma Stocks Sink and Trainline Faces Competition | The FTSE 100 index, a barometer of the UK’s economic health, hit a speed bump this week. After a remarkable 16-day winning streak, it closed down 0.4 percent on Wednesday. The culprit? A sharp decline in pharmaceutical stocks, triggered by ... |
| 09.05.2025 | A New Chapter in US-UK Trade: Hope Amidst Tariffs | In a world where trade agreements often resemble a high-stakes poker game, the recent US-UK trade deal is a modest hand dealt at the table. On May 8, 2025, President Donald Trump and British Prime Minister Keir Starmer announced a limited b... |
| 09.05.2025 | Imfinzi improved DFS in early bladder cancer | Imfinzi improved DFS in early bladder cancer
Fri, May 09, 2025 08:00 CET Report this content
09 May 2025
Imfinzi regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non... |
| 09.05.2025 | Trump, Starmer hail limited US-UK trade deal, but 10% duties remain | Trump, Starmer hail limited US-UK trade deal, but 10% duties remain
By Andrea Shalal, Alistair Bell and Andrew MacaskillMay 8, 202510:16 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
SummaryCo... |
| 08.05.2025 | Tempus AI Stock: Time to Double Down or Cut and Run? Tempus AI is gaining traction and on track for profits this year; high short interest and rising institutional activity point to significant upside... |
[content-module:CompanyOverview|NASDAQ:TEM]
Tempus AI (NASDAQ: TEM) is an interesting AI story that operates a platform and library for diagnosis and drug discovery. The platform aids physicians by enabling personalized care for hard-to-tr... |
| 07.05.2025 | The Future of Marketing and Medicine: Innovations Shaping Tomorrow | In the fast-paced world of technology and healthcare, two recent developments stand out. Jasper, a leader in AI marketing, has launched a Customer Advisory Board (CAB) to steer its future. Meanwhile, Ousia Pharma, a biotech company from Cop... |
| 07.05.2025 | FTSE 100’s record run ends as pharma stocks slide on new Trump appointment | The FTSE 100’s record run came to an end on Wednesday as pharma stocks slumped on the back of a controversial US regulatory appointment.
The blue-chip index spent the entire session in the red and closed off 0.4 per cent.
Drugmakers GSK and... |
| 07.05.2025 | Novo Nordisk shares pop as drugmaker sees copycat Wegovy sales easing in 2025 | Shares of Novo Nordisk climbed on Wednesday after it said that sales of its blockbuster Wegovy weight loss drug were seen improving in the second half of the year as copycat compounded drugs are phased out.
The Danish pharmaceutical giant r... |
| 07.05.2025 | Enhertu improved pCR in early-stage breast cancer | Enhertu improved pCR in early-stage breast cancer
Wed, May 07, 2025 08:30 CET Report this content
07 May 2025
Enhertufollowed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complet... |
| 06.05.2025 | Jasper Launches Customer Advisory Board | Jasper, the world’s leading AI marketing platform, today announced the launch of its Customer Advisory Board (CAB), which features senior leaders from globally recognized, industry-leading organizations, including prominent members of the S... |
| 06.05.2025 | Calquence combination approved in EU for 1L MCL | Calquence combination approved in EU for 1L MCL
Tue, May 06, 2025 08:02 CET Report this content
06 May 2025
Calquence plus chemoimmunotherapy approved in the EU
as first and only BTK inhibitor for 1st-line mantle cell lymphoma
Approval base... |
| 06.05.2025 | Ousia Pharma Raises Seed Funding | Ousia Pharma, a Copenhagen, Denmark-based biotech company providing a new drug class for obesity, raised an undisclosed amount in Seed funding.
Omega Funds made the investment.
The company intends to use the funds to support the preclinical... |
| 02.05.2025 | Breztri met primary endpoints in Ph3 asthma trials | Breztri met primary endpoints in Ph3 asthma trials
Fri, May 02, 2025 08:00 CET Report this content
02 May 2025
Breztri met primary endpoints in KALOS and LOGOS Phase III trials in asthma
Positive high-level results from the Phase III KALOS ... |
| 02.05.2025 | AI offers vital support for dementia care but risks remain high | - |
| 01.05.2025 | Director/PDMR Shareholding | Director/PDMR Shareholding
Thu, May 01, 2025 17:00 CET Report this content
1 May 2025
Transaction by Person Discharging Managerial Responsibilities
AstraZeneca PLC (the Company) announces that it was notified on 1 May 2025 that Karen Knudse... |
| 30.04.2025 | AstraZeneca May Face Another China Fine Over Suspected Unpaid Import Taxes | (Yicai) April 30 -- AstraZeneca, the UK-Swedish pharmaceutical giant being investigated by Chinese regulators, said it could face another fine in China of as much as USD8 million for suspected unpaid import taxes.
The potential new fine wou... |
| 29.04.2025 | The Future of Cancer Diagnostics: A New Era of Liquid Biopsy Testing | In the ever-evolving landscape of cancer diagnostics, a quiet revolution is underway. Liquid biopsy testing is emerging as a game-changer, offering a less invasive, more efficient way to monitor and treat cancer. At the forefront of this tr... |
| 29.04.2025 | AstraZeneca's Calquence: A New Dawn for CLL Treatment in Europe | AstraZeneca is on the brink of a breakthrough. The European Medicines Agency (EMA) has recommended the approval of a fixed-duration regimen of Calquence (acalabrutinib) for treating chronic lymphocytic leukaemia (CLL). This recommendation, ... |
| 29.04.2025 | Fixed-duration Calquence recommended in EU for CLL | Fixed-duration Calquence recommended in EU for CLL
Tue, Apr 29, 2025 08:10 CET Report this content
29 April 2025
Fixed-duration Calquence-based regimens recommended for approval
in the EU by CHMP for 1st-line chronic lymphocytic leukaemia
R... |
| 29.04.2025 | 1st Quarter Results | 1st Quarter Results
Tue, Apr 29, 2025 08:00 CET Report this content
Click on, or paste, the following link into your web browser, to view the associated PDF document.
http://www.rns-pdf.londonstockexchange.com/rns/5152G_1-2025-4-28.pdf
29 A... |
| 29.04.2025 | Перечень жизненно важных лекарств не резиновый | - |
| 29.04.2025 | HSBC becomes latest brokerage to cut S&P 500 annual target below 6000 mark | HSBC becomes latest brokerage to cut S&P 500 annual target below 6000 mark
By ReutersApril 29, 20251:17 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
A logo of HSBC is seen on its headquar... |
| 29.04.2025 | Update on CAPItello-280 Phase III trial | Update on CAPItello-280 Phase III trial
Tue, Apr 29, 2025 08:05 CET Report this content
29 April 2025
Update on CAPItello-280 Phase III trial of Truqap in metastatic castration-resistant prostate cancer
AstraZeneca is discontinuing the CAPI... |
| 29.04.2025 | AstraZeneca’s Soriot Warns US Against Trade Tariffs on Medicines | AstraZeneca Plc’s Chief Executive Officer Pascal Soriot warned that trade tariffs are not the best way to manage pharmaceuticals and that drugmakers are calling for no additional US levies on medicines.
“We actually believe that a better in... |
| 29.04.2025 | SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR | BOSTON and ROLLE, Switzerland, April 29, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and global leader in data-driven medicine, today announced the expansion of its ongoing collaboration... |
| 29.04.2025 | Shipping volume will plummet 35% next week, LA port official says in CNBC interview | Shipping volume will plummet 35% next week, LA port official says in CNBC interview
By ReutersApril 29, 20252:15 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Shipping containers are shown at ... |
| 28.04.2025 | Фармрынок идет на поправку | - |
| 28.04.2025 | UK dividends slump in 2025 after cuts from Vodafone and Burberry | UK dividends totalled just £14bn in the first quarter of 2024, a 4.6 per cent decline from last year, thanks to major cuts from key companies like Vodafone and Burberry.
While regular dividends only fell by 0.2 per cent, a 3.3 percentage po... |
| 25.04.2025 | China grants some exemptions from US tariffs to limit trade war pain | China has granted some exemptions on US imports from its 125 per cent tariffs and is asking them to identify goods that could be eligible, according to businesses notified.
This is the clearest sign yet that Beijing is worried about the eco... |
| 25.04.2025 | US business lobby in China: Some pharma firms reporting tariff exemptions | US business lobby in China: Some pharma firms reporting tariff exemptions
By Andrew Silver and Brenda GohApril 25, 20254:08 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
SummaryCompanies
US bu... |
| 24.04.2025 | HCLTech and Thermo Fisher: A Tale of Growth Amidst Uncertainty | In the world of business, growth is the lifeblood. Companies thrive on it, investors crave it, and economies depend on it. Recently, two companies have emerged as beacons of hope in their respective sectors: HCLTech in India and Thermo Fish... |
| 24.04.2025 | Thermo Fisher Scientific receives the Key to Gothenburg | Thermo Fisher Scientific receives the Key to Gothenburg
Thu, Apr 24, 2025 08:01 CET Report this content
The world leader in serving science, Thermo Fisher Scientific, will open a new European lab operation in Gothenburg. Yesterday, Leon Wys... |
| 23.04.2025 | Tariffs and Silence: The Economic Storm on the Horizon | The U.S. economy stands at a crossroads, teetering on the edge of recession. Citigroup's Chief Economist Nathan Sheets has raised the alarm, estimating a 40% to 45% chance of economic downturn. The culprit? Tariffs. These trade barriers, in... |
| 23.04.2025 | The Winds of Change: How Political Decisions Are Shaping America's Offshore Energy Future | The offshore wind industry in the United States is at a crossroads. Recent political maneuvers have cast a long shadow over a sector that once promised to be a beacon of growth and innovation. The Trump administration's recent decision to h... |
| 23.04.2025 | Complementary and Alternative Medicine Market Size Worth USD 1,282.70 Bn by 2034 | According to Precedence Research, the global complementary and alternative medicine market size is estimated to be worth USD 1,282.70 billion by 2034, up from USD 193.36 billion in 2025. The Europe complementary and alternative medicine mar... |
| 23.04.2025 | Astrazeneca chief blasts Europe for ‘putting citizens’ health at risk’ | Europe is putting its “ability to protect the health of its own people at risk” by not investing enough, the chief executive of FTSE 100 giant Astrazeneca has warned.
Pascal Soriot added that the continent is “falling behind” in attracting ... |
| 22.04.2025 | Roche to invest $50 billion in the U.S. as pharma tariff threat lingers | The investment will create more than 12,000 jobs, Roche said — 1,000 with the company, and the remainder to support new U.S. manufacturing capabilities.
Pharmaceutical companies have been scrambling to bolster their U.S. presence amid threa... |
| 22.04.2025 | As FTSE 100 pharma firms wait for a tariffs decision, what would drugs levies mean for consumers? | For FTSE 100 businesses navigating the shifting sands of Trump’s trade war, the uncertainty surrounding the tariffs has been almost as painful as the stock market shocks.
The pharmaceutical industry has been left in a particularly agonising... |
| 22.04.2025 | Docquity and AstraZeneca's Patient Support Program Educates Tens of Thousands in Thailand | OAZisCare, digitally powered by DocquityCare, has advanced patient education and adherence for cancer care and RSV vaccines since 2024
The collaboration helps tackle Southeast Asia's healthcare needs, with 85.7% of doctors noting immunizati... |
| 22.04.2025 | Enhertu combination improved PFS in 1L HER2+ mBC | Enhertu combination improved PFS in 1L HER2+ mBC
Tue, Apr 22, 2025 08:00 CET Report this content
This announcement contains inside information
22 April 2025
Enhertu plus pertuzumab demonstrated highly statistically significant and clinicall... |
| 22.04.2025 | Commentary: The silence of CEOs speaks volumes about corporate leadership today | IPING, United Kingdom: Mr President, history is clear that tariffs raise prices, unemployment and inequality while lowering productivity and economic growth. The US central bank chair said as much on Wednesday (Apr 16).
As chief executive o... |
| 17.04.2025 | Eli Lilly’s weight loss pill succeeds in first late-stage trial on diabetes patients; shares jump 14% | Eli Lilly said its daily obesity pill met the company’s goals in the first of several closely watched late-stage trials.
The pill helped Type 2 diabetes patients lower their blood sugar and body weight and showed safety on par with popular ... |
| 16.04.2025 | Government scrambles to swerve Trump pharma tariffs | A race against time is underway to shield the UK pharmaceutical sector from potentially swinging Trump tariffs on imported drugs.
As it stands, there is an exemption for pharmaceuticals on the baseline 10 per cent tariffs for goods coming i... |
| 15.04.2025 | Назад, в генетическое будущее | - |
| 13.04.2025 | The Intersection of Innovation and Investment: Insights from the Harvard College China Forum | In the hallowed halls of Harvard University, the 28th Harvard College China Forum unfolded from April 4 to April 6, 2025. This gathering, a beacon for dialogue between East and West, drew leaders from various sectors. Among them was Wei Zho... |
| 13.04.2025 | Gothenburg: The Healthtech Launchpad of the Nordics | Gothenburg is more than just a city; it’s a beacon for healthtech innovators. Nestled in Sweden, the city stands as the largest healthcare market in the Nordic region. With a population of 10.5 million and a robust healthcare spending frame... |
| 12.04.2025 | Global Times: Believing in China, believing in tomorrow | BEIJING, April 12, 2025 /PRNewswire/ -- "Believing in China" has become a buzz phrase this spring.
"For us, opportunities exist in all Chinese cities" and "China's scientific and technological innovation ecosystem i... |
| 11.04.2025 | Tariff Turmoil: The Ripple Effect on the FTSE 100 Banks | The financial landscape is a battlefield, and the FTSE 100 banks are caught in the crossfire. As tariffs rise and fall like a pendulum, the impact on these institutions is profound. The recent first-quarter results season is a litmus test f... |
| 11.04.2025 | Why health innovators are turning to Gothenburg | Why health innovators are turning to Gothenburg
Fri, Apr 11, 2025 15:13 CET Report this content
On 7-9 April, around 30 innovative companies from 10 countries took part in a three-day bootcamp designed to fast-track their entry into the Swe... |
| 11.04.2025 | Result of AGM | Result of AGM
Fri, Apr 11, 2025 18:30 CET Report this content
11 April 2025
Results of Annual General Meeting held on 11 April 2025
AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed i... |
| 11.04.2025 | Gothenburg - a launch pad for health innovators | Gothenburg - a launch pad for health innovators
Fri, Apr 11, 2025 15:13 CET Report this content
As the Nordic region’s largest healthcare market and a leading life science nation, Sweden is an attractive environment for healthtech companies... |
| 11.04.2025 | Why are European stocks holding up much better than U.S. equities amid the trade war? | - |
| 10.04.2025 | Tariff Turmoil: The Pharmaceutical Industry Faces a Storm | The pharmaceutical industry is in the eye of a storm. President Donald Trump has thrown a wrench into the works with his proposed tariffs on drug imports. The news sent shockwaves through global markets, causing shares of major pharmaceutic... |
| 10.04.2025 | Tariff Tango: The Global Market's Rollercoaster Ride | The world of finance is a high-stakes game. One moment, stocks soar; the next, they plummet. The recent dance of tariffs has sent markets into a frenzy, leaving investors reeling. U.S. President Donald Trump’s trade policies have been a whi... |
| 10.04.2025 | Global pharma shares plunge as Trump doubles down on tariff threat | Global drugmakers' stocks dropped across the board after US President Donald Trump reiterated plans for a "major" tariff on pharmaceutical imports, threatening an interwoven global supply chain, and as his country-specific recipro... |
| 10.04.2025 | Autos, pharma, luxury and more: The global sectors soaring after Trump’s tariffs walkback | European stocks soared on Thursday after U.S. President Donald Trump’s jarring about-turn on most tariffs.
Tensions between Washington and Beijing remain high, however, with Trump ratcheting up duties on goods from China to 125% and citing ... |
| 09.04.2025 | Astrazeneca, BP, HSBC: The FTSE 100 stocks hit by Trump and China’s trade war | The global trade war has kicked into a new gear and it’s bad news for some of the FTSE 100’s biggest firms.
Numerous giants on the UK’s flagship index have significant exposure to Asia and more importantly one of Trumps biggest targets – Ch... |
| 09.04.2025 | FTSE 100 slumps as EU and China launch retaliatory tariffs against US | The FTSE 100 closed in the red on Wednesday, reversing gains made at the start of the week.
The blue-chip index was off 2.9 per cent. Pharma stocks drove losses on the back of fresh tariff threats from President Donald Trump.
Astrazeneca cl... |
| 09.04.2025 | Pharmaceutical stocks rise as Trump pauses tariffs but not for China | Some pharmaceutical stocks rose after President Donald Trump said he would pause most so-called reciprocal tariffs, temporarily easing fears about the impact of potential tariffs on pharmaceuticals .
Shares of most U.S.-based companies turn... |
| 09.04.2025 | Trump tariffs kick in, spurring more market carnage | WASHINGTON: United States President Donald Trump's "reciprocal" tariffs on dozens of countries took effect on Wednesday (Apr 9), including massive 104 per cent duties on Chinese goods, deepening his global trade war and spurring m... |
| 09.04.2025 | European stocks close 3.5% lower as Trump tariffs take effect, China and EU retaliate | This was CNBC’s live blog covering European markets.
European stocks closed sharply lower on Wednesday, with Tuesday’s market rebound proving short-lived as the U.S.′ country-specific tariffs started taking effect.
The pan-European Stoxx 60... |
| 09.04.2025 | Trump’s plan for tariffs on drugmakers sinks FTSE 100 pharma stocks | Pharmaceutical imports became the latest target for President Donald Trump’s tariffs, sending FTSE 100 drugmakers stock into the red.
Astrazeneca plunged seven per cent and GSK 5.7 per cent. Haleon closed off over three per cent.
This follo... |
| 04.04.2025 | Tariff Turmoil: The Ripple Effect of Trump's Trade War on UK Markets | The world of finance is a delicate dance, and right now, the music has turned discordant. The recent tariffs imposed by US President Donald Trump have sent shockwaves through UK markets, leaving investors scrambling and businesses reeling. ... |
| 04.04.2025 | Tariff Turmoil: The Ripple Effects of Trump's Trade Policies on Global Markets | In the world of finance, news travels fast. The recent announcement of sweeping tariffs by U.S. President Donald Trump sent shockwaves through global markets. The FTSE 100, a barometer of the UK’s largest companies, opened 1.4 percent lower... |
| 04.04.2025 | Enhertu approved in EU in post-ET breast cancer | Enhertu approved in EU in post-ET breast cancer
Fri, Apr 04, 2025 08:00 CET Report this content
04 April 2025
Enhertu approved in the EU as first HER2-directed therapy for patients with HR-positive, HER2-low or HER2-ultralow metastatic brea... |
| 04.04.2025 | Imfinzi approved in EU for AEGEAN | Imfinzi approved in EU for AEGEAN
Fri, Apr 04, 2025 08:05 CET Report this content
04 April 2025
Imfinzi-based perioperative regimen approved in the EU for resectable non-small cell lung cancer
Approval based on AEGEAN Phase III trial result... |
| 03.04.2025 | US tariffs: Keir Starmer vows to ‘keep cool head’ in face of ‘economic impact’ | Sir Keir Starmer has vowed to “keep a cool head” in the face of the “economic impact” of Donald Trump’s 10 per cent tariffs on UK exports to the US, amid fears of a wider trade war.
The Prime Minister spoke to business chiefs in Downing Str... |
| 03.04.2025 | Pharma tariff relief likely short-lived with sector-specific duties on the horizon | Pharmaceutical companies breathed a sigh of relief Wednesday after U.S. President Donald Trump revealed that they would not be subject to reciprocal tariffs — but that reprieve could prove fleeting.
The Trump administration is considering a... |
| 03.04.2025 | FTSE 100 pharma giants GSK and Astrazeneca appear to swerve Trump tariffs | FTSE 100 pharma giants GSK and Astrazeneca may have escaped the worst of US President Donald Trump’s tariffs, according to a City broker.
Pharmaceutical goods appear to be exempt from higher-rate tariffs introduced by President Trump in his... |
| 02.04.2025 | Latest Innovation in Automation and AI/ML Presented at the 11th Annual Biopharma Partner Symposium | Digitalizing Biopharma R&D: The Genedata Biopharma Platform is the #1 enterprise software system for achieving operational excellence in biopharma R&D.
Top biopharmas and leading biotechs discuss new trends in AI/ML and share how th... |
| 02.04.2025 | ONTOFORCE Announces Enhanced Functionality in DISQOVER to Build Cohorts in Minutes | ONTOFORCE announces enhanced cohort-building functionality in DISQOVER
Life sciences companies can now maximize the value of their clinical data to conduct faster, more cost-effective hypothesis testing with DISQOVER's newly enhanced Cohort... |
| 01.04.2025 | Global Times: China remains an 'ideal, secure and promising' destination for foreign investors: Xi | BEIJING, April 1, 2025 /PRNewswire/ -- As China wraps up a week in which it hosted two top-level international forums - the China Development Forum (CDF) 2025 and the Boao Forum for Asia (BFA) Annual Meeting 2025 - to drive home its commitm... |
| 01.04.2025 | Trump’s tariffs are a new challenge for Big Pharma. Here are the best-positioned stocks | - |
| 31.03.2025 | AstraZeneca's Breakthroughs: A New Dawn in Cancer Treatment | In the realm of oncology, AstraZeneca is carving a path through the dense forest of cancer treatment. Two recent approvals highlight this journey: Calquence for mantle cell lymphoma (MCL) and Imfinzi for muscle-invasive bladder cancer (MIBC... |
| 31.03.2025 | Calquence recommended for EU approval in 1L MCL | Calquence recommended for EU approval in 1L MCL
Mon, Mar 31, 2025 08:05 CET Report this content
31 March 2025
Calquence plus chemoimmunotherapy recommended for approval in the EU by CHMP as first and only BTK inhibitor for 1st-line mantle c... |
| 31.03.2025 | Imfinzi approved in the US for bladder cancer | Imfinzi approved in the US for bladder cancer
Mon, Mar 31, 2025 08:00 CET Report this content
31 March 2025
Imfinzi approved in the US as first and only perioperative
immunotherapy for patients with muscle-invasive bladder cancer
Based on N... |
| 26.03.2025 | Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca | AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC
SEOUL, South Korea, March 26, 2025 /PRNewswi... |
| 25.03.2025 | The Weight of Expectations: A Look at the Obesity Drug Market's Rollercoaster Ride | The obesity drug market is a battleground, where hopes soar and plummet with each trial result. Recent developments from Novo Nordisk and Eli Lilly illustrate this volatile landscape. Both companies are vying for dominance in a sector proje... |
| 25.03.2025 | Tariff Flexibility: A Double-Edged Sword for Markets | In the world of finance, uncertainty is like a storm cloud. It looms, casting shadows over markets and making investors uneasy. Recently, U.S. President Donald Trump hinted at “flexibility” regarding tariffs. This word, while seemingly beni... |
| 24.03.2025 | Eli Lilly will soon release key data on its weight loss pill. Here’s why it could be a game-changer | Eli Lilly plans to release initial results from several late-stage clinical trials on its experimental once-daily obesity pill, orforglipron, this year.
The trial results are among the pharmaceutical industry’s most critical of the year, as... |
| 24.03.2025 | Assemblin conducts extensive multi-project for AstraZeneca | Assemblin conducts extensive multi-project for AstraZeneca
Mon, Mar 24, 2025 08:00 CET Report this content
Assemblin has been assigned responsibility for multi-technical installations in plumbing, industrial pipes, fire alarms, electricity,... |
| 24.03.2025 | Sermonix and Regor Announce Strategic Collaboration to Optimize Regor's Proprietary rCARD Platform for Identification of Novel Targets and Therapeutics | Partnership aims to develop efficacious and well-tolerated treatments for advanced metastatic breast cancer
COLUMBUS, Ohio, and CAMBRIDGE, Mass., March 24, 2025 /PRNewswire/ -- Sermonix Pharmaceuticals, a privately held biopharmaceutical co... |
| 24.03.2025 | Beijing pledges greater market access as top global CEOs gather at the China Development Forum | China’s Vice Premier He Lifeng has reassured foreign business leaders that Beijing will continue to open up its market and welcome more investment from multinational companies, according to a readout from the Ministry of Commerce.
Foreign C... |
| 24.03.2025 | CNBC Daily Open: Tariff flexibility sounds good, but also signals uncertainty | “Flexibility” connotes openness to change. U.S. President Donald Trump expressed Friday the possibility of being flexible with tariffs, which may have helped stocks tick up, pushing the three key U.S. benchmarks into the green for the week.... |
| 22.03.2025 | America needs a jab in its corporate backside | - |
| 21.03.2025 | AstraZeneca's Bold Leap into Beijing: A New Era for Biopharmaceutical Innovation | AstraZeneca is making waves in the biopharmaceutical ocean. The company recently announced a staggering $2.5 billion investment in Beijing. This move is not just a financial commitment; it’s a strategic pivot that could reshape the landscap... |
| 21.03.2025 | AZN invests $2.5bn in Beijing R&D & manufacturing | AZN invests $2.5bn in Beijing R&D & manufacturing
Fri, Mar 21, 2025 12:37 CET Report this content
21 March 2025
AstraZeneca to invest $2.5 billion in new global strategic R&D centre, biotech agreements and manufacturing in Beiji... |
| 21.03.2025 | NVIDIA GTC: AI Innovation Driving Change in Healthcare and Drug Discovery | - |
| 21.03.2025 | Syneron Bio Announces Strategic Collaboration with AstraZeneca | BEIJING, March 21, 2025 /PRNewswire/ -- Syneron Bio, a cutting-edge oral macrocyclic peptide drug biotech company, announced today a strategic collaboration with the global biopharmaceutical leader AstraZeneca to develop potential first-in-... |
| 21.03.2025 | AstraZeneca to invest $2.5 billion in Beijing hub as it looks beyond Chinese tax probe | British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development center in Beijing, China.
Under the deal, AstraZeneca will enter research and development collaborations with biotec... |
| 21.03.2025 | Five alternative European tech clusters that are leading the way | Across Ireland there are more than 3,000 so-called holy wells sites aligned with pagan and early Christian beliefs that these sites were thought to miraculous powers. While the spread of alternative tech clusters around Europe may not be bl... |
| 21.03.2025 | Harbour BioMed Enters into Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Therapeutic Antibodies | SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, March 21, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeut... |
| 20.03.2025 | Sustainability in Business: The New Gold Standard | In the modern business landscape, sustainability is no longer a buzzword; it’s a necessity. Companies are under increasing pressure to adopt responsible practices. This shift is driven by consumers, investors, and regulatory bodies. The sta... |
| 20.03.2025 | European Markets Shudder as Wall Street Sells Off and Turkish Turmoil Unfolds | European markets are feeling the tremors of Wall Street's recent sell-off. On March 19, 2025, the pan-European STOXX 600 index dipped by 0.1%, following a rough day for U.S. stocks. Investors are on edge, grappling with fears of a slowdown ... |
